> Back to seminars list

Seminar

Friday, 21st, January 2022
11h30
Centre de recherche - Paris - Amphithéâtre Hélène Martel-Massignac (BDD)

The role of lncRNAs in cancer

The human genome is pervasively transcribed, producing a highly complex transcriptome including thousands of so-called long non-coding RNAs (lncRNAs). Expression of these lncRNAs is deregulated in virtually all cancer types and mechanistic studies suggest they act as regulators of various biological processes or signaling cascades. Together with their often tissue restricted expression, these features put forward lncRNAs as attractive therapeutic targets. I will present our efforts to identify functionally relevant lncRNAs in cancer and the mechanisms by which they operate. 

Speaker(s)

Prof. Pieter Mestdagh
full professor at Ghent University and group leader at the Cancer Research Institute Ghent (CRIG), Ghent University

the Cancer Research Institute Ghent (CRIG)

Invited by

Dr. Chunlong Chen
Group Leader
Dynamique de l'information génétique : bases fondamentales et cancer (DIG-Cancer) (UMR3244)

Institut Curie

Learn more

Pieter Mestdagh is a full professor at Ghent University and group leader at the Cancer Research Institute Ghent (CRIG). His lab is focused on studying the role of non-coding RNAs in cancer by combining functional genomics and applied bioinformatics approaches. The lab has a recognized expertise in gene expression data analysis and developed several research tools, databases and data analysis methods dedicated to the study of non-coding RNAs. Pieter Mestdagh is co-founder of various international consortia related to the study of ncRNAs including the miRNA Quality Control consortium (miRQC), the extracellular vesicles Quality Control study (evQC), the extracellular RNA Quality Control study (exRNAQC) and the RNA-Atlas consortium.Pieter Mestdagh authored more than 100 articles in international peer reviewed journals and is an inventor on several patents. Some of the tools he developed are licensed to commercial companies and he’s the scientific co-founder of Flamingo Therapeutics, a clinical stage biotech company developing lncRNA therapeutics in cancer . His work has been awarded with various national prices and he was nominated among the top 5 young investigators in Belgium and the Netherlands by The New Scientist.